Abstract
Axial spondylarthritis (axSpA) is a chronic inflammatory disease. Inflammatory changes of the axial and peripheral musculoskeletal system and possible extra-musculoskeletal manifestations may cause debilitating pain, functional disability, limited mobility, and missed days at work, i.e. may diminish the quality of life.
Currently, this disease can be treated and remission achieved, using both non-pharmacological and ever widening portfolio of pharmacological approaches. In 2022, ASAS-EULAR issued an update concerning the recommendations for the treatment of axSpA, respecting the new treatment possibilities.
Tailored therapy thus enters our approach to the patient, based on the main axSpA symptoms (dominantly axial versus peripheral), presence of extra-musculoskeletal manifestations, and comorbidities. ASAS-EULAR 2022 recommendations adjust the axSpA therapy with respect to disease-modifying drugs and both biological (inhibitors of tumor-necrosis factor and interleukin 17) and targeted synthetic agents (Janus kinase inhibitors).